Hepatic-metastasized adenocarcinomas of the stomach and gastroesophageal junction: multimodal treatment with gastrectomy/esophagectomy and resection or ablation of the metastases

Hepatic-metastasized adenocarcinomas of the stomach and gastroesophageal junction: multimodal treatment with gastrectomy/esophagectomy and resection or ablation of the metastases - HAMMER trial

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00037712

Enrollment

Registered

2025-12-11

Start date

2026-01-16

Completion date

Unknown

Last updated

2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C16 C15

Interventions

Group 1: Patients with hepatic-metastasized adenocarcinomas of the stomach and gastroesophageal junction receive, as part of a multimodal therapy, a resection and treatment of all metastases (resectio

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Histologically confirmed gastric or gastroesophageal junction adenocarcinoma with hepatic metastases Medical and technical resectability of the primary tumor: metastatic lesions are resectable or can be controlled by a local ablative procedure (interdisciplinary assessment) Existing recommendation from an interdisciplinary tumor board supporting resection as part of an individualized treatment concept Additional non-hepatic metastases may be included: Localized, potentially resectable peritoneal carcinomatosis; Lung: potentially resectable or otherwise treatable; unilateral or bilateral Krukenberg tumors (ovarian metastases); Unilateral or bilateral adrenal metastases; Extra-abdominal lymph node metastases such as supraclavicular or cervical lymph node involvement; Localized bone involvement (defined as within a radiation field) or other metastatic disease sites deemed resectable by the investigator and confirmed by the review committee The patient is mentally and physically capable of understanding the meaning and implications of the study Written informed consent

Exclusion criteria

Exclusion criteria: Functional inoperability Non-resectable primary tumor (adenocarcinoma of the stomach or gastroesophageal junction) Concurrent participation in another interventional study Pregnancy Severe psychopathological findings and pre-existing conditions, e.g., active psychosis

Design outcomes

Primary

Measure	Time frame
Overall survival 2 years postoperatively	—

Secondary

Measure	Time frame
Quality of Life questionnaire C30 (EORTC-QLQ-C30) Completion rate of postoperative systemic therapy 1-, 3-, and 5-year survival Progression-free survival up to 5 years postoperatively 30- and 90-day morbidity and mortality	—

Countries

Germany

Contacts

Public ContactAndreas Kroh

Uniklinik RWTH Aachen, Klinik für Allgemein-, Viszeral-, Kinder- und Transplantationschirurgie

akroh@ukaachen.de+49 241 80 35478

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Mar 14, 2026